Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (31-40 of 190) with videos related to

Pageof 19
Sort By:
Current Opinion in Rheumatology|February 19, 2010
Kinase inhibitors: a new approach to rheumatoid arthritis treatmentStanley Cohen, Roy Fleischmann
Annals of the Rheumatic Diseases|October 19, 2014
Response to: 'Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry' by Favalli et alRoy Fleischmann, Eustratios Bananis
Annals of the Rheumatic Diseases|June 5, 2014
Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?Roy Fleischmann, Yusuf Yazici
Drugs & Aging|March 17, 2007
Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritisRoy Fleischmann, Imran Iqbal
Arthritis Research & Therapy|July 2, 2004
Does safety make a difference in selecting the right TNF antagonist?Roy Fleischmann, David Yocum
Current Rheumatology Reports|April 18, 2007
Treatment of osteoarthritis with anakinraImran Iqbal, Roy Fleischmann
Expert Opinion on Drug Safety|June 5, 2020
Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritisRoy Fleischmann, Daniel E Furst
Arthritis Research & Therapy|February 2, 2020
Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation? Comment on article by Boeters DM et alAlfonse T Masi, Roy Fleischmann
Rheumatology (Oxford, England)|October 14, 2011
Safe and well toleratedRoy Fleischmann, Nicola Goodson, Dirk Elewaut
Expert Opinion on Biological Therapy|July 23, 2004
Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritisRoy Fleischmann, Richard Stern, Imran Iqbal
Pageof 19

Showing results (31-40 of 190) with videos related to

Sort By:
Pageof 19
Current Opinion in Rheumatology|February 19, 2010
Kinase inhibitors: a new approach to rheumatoid arthritis treatmentStanley Cohen, Roy Fleischmann
Annals of the Rheumatic Diseases|October 19, 2014
Response to: 'Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry' by Favalli et alRoy Fleischmann, Eustratios Bananis
Annals of the Rheumatic Diseases|June 5, 2014
Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?Roy Fleischmann, Yusuf Yazici
Drugs & Aging|March 17, 2007
Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritisRoy Fleischmann, Imran Iqbal
Arthritis Research & Therapy|July 2, 2004
Does safety make a difference in selecting the right TNF antagonist?Roy Fleischmann, David Yocum
Current Rheumatology Reports|April 18, 2007
Treatment of osteoarthritis with anakinraImran Iqbal, Roy Fleischmann
Expert Opinion on Drug Safety|June 5, 2020
Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritisRoy Fleischmann, Daniel E Furst
Arthritis Research & Therapy|February 2, 2020
Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation? Comment on article by Boeters DM et alAlfonse T Masi, Roy Fleischmann
Rheumatology (Oxford, England)|October 14, 2011
Safe and well toleratedRoy Fleischmann, Nicola Goodson, Dirk Elewaut
Expert Opinion on Biological Therapy|July 23, 2004
Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritisRoy Fleischmann, Richard Stern, Imran Iqbal
Pageof 19